Literature DB >> 3124079

Binding of 131I-labeled tissue-type plasminogen activator on de-endothelialized lesions in rabbits.

A Uehara1, Y Isaka, H Etani, K Kimura, S Yoneda, T Kamada, T Kozuka, M Nobuhara.   

Abstract

Tissue-type plasminogen activator (t-PA) which has a high affinity for fibrin in the clot, was labeled with 131I by the iodogen method, and its binding to de-endothelialized lesions in the rabbit was measured to assess the detectability of thrombi. The de-endothelialized lesion was induced in the abdominal aorta with a Fogarty 4F balloon catheter. Two hours after the de-endothelialization, 131I-labeled t-PA (125 +/- 46 microCi) was injected intravenously. The initial half-life of the agent in blood (n = 12) was 2.9 +/- 0.4 min. The degree of binding of 131I-labeled t-PA to the de-endothelialized lesion was evaluated at 15 min (n = 6) or at 30 min (n = 6) after injection of the agent. In spite of the retention of the biochemical properties of 131I-labeled t-PA and the presence of fibrin deposition at the de-endothelialized lesion, the binding of t-PA to the lesion was not sufficiently strong. Lesion-to-control ratios (cpm/g/cpm/g) were 1.65 +/- 0.40 (at 15 min) and 1.39 +/- 1.31 (at 30 min), and lesion-to-blood ratios were 1.39 +/- 0.32 (at 15 min) and 1.36 +/- 0.23 (at 30 min). These results suggest that radiolabeled t-PA may be inappropriate as a radiopharmaceutical for the scintigraphic detection of a pre-existing thrombotic lesion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124079

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  2 in total

1.  In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.

Authors:  E Tsukamoto
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

2.  Tc-99m labeled tissue-type plasminogen activator: preparation, stability and preliminary imaging of thrombus-bearing rats.

Authors:  K Itoh; E Tsukamoto; T Nishibe; S Sakurama; M Ieko; T Tanabe; M Furudate
Journal:  Ann Nucl Med       Date:  1991-07       Impact factor: 2.668

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.